|
| 37291235 | Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. | NPJ Breast Cancer | 2023 |
| 36216884 | Intratumour heterogeneity, from hypothesis to the clinic. | British Journal of Cancer | 2023 |
| 37608772 | Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer | J Pathol | 2023 |
| 37608771 | Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. | J Pathol | 2023 |
| 37607325 | De Novo Oligometastatic Breast Cancer. | J Clin Oncol | 2023 |
| 37935787 | Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy. | | 2023 |
| 37935109 | Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. | J Natl Compr Canc Netw | 2023 |
| 37841335 | Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms. | Comput Struct Biotechnol J | 2023 |
| 37923752 | Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. | Nat Commun | 2023 |
| 37656608 | Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. | | 2023 |
| 37913680 | Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. | Eur J Cancer | 2023 |
| 37991241 | Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer. | | 2023 |
| 37972336 | Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. | JCO Precis Oncol | 2023 |
| 37966841 | Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. | | 2023 |
| 37693586 | Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221. | Res Sq | 2023 |
| 37688650 | Associations amongst genes, molecules, cells, and organs in breast cancer metastasis. | | 2023 |
| 37615099 | Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. | Pharmacogenomics | 2023 |
| 37767612 | Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials? | | 2023 |
| 37348030 | Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look? | | 2023 |
| 37410451 | Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. | JAMA Oncol | 2023 |
| 37467337 | More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome. | Sci Adv | 2023 |
| 36650408 | Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing. | | 2023 |
| 36649570 | Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. | J Clin Oncol | 2023 |
| 36647745 | Thymidine kinase activity levels in serum can identify HR+⿿metastatic breast cancer patients with a low risk of early progression (SWOG S0226). | Biomarkers | 2023 |
| 37400619 | ASO Visual Abstract: Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancers-Catching up with the Rest. | | 2023 |
| 36813666 | In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. | Vaccine | 2023 |
| 37391697 | Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HRâ¿¿+) breast cancer. | | 2023 |
| 36634607 | Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. | J Natl Compr Canc Netw | 2023 |
| 36634296 | Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. | JCO Precis Oncol | 2023 |
| 36623515 | Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Oncol | 2023 |
| 37380659 | Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. | NPJ Breast Cancer | 2023 |
| 37378695 | Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. | | 2023 |
| 36866462 | Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. | Oncologist | 2023 |
| 37179362 | Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. | NPJ Breast Cancer | 2023 |
| 37433103 | Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. | J Clin Oncol | 2023 |
| 36989609 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. | J Clin Oncol | 2023 |
| 37349612 | Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest. | | 2023 |
| 35139274 | Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. | N Engl J Med | 2022 |
| 35903931 | Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. | Clin Cancer Res | 2022 |
| 35513244 | Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. | Ann Oncol | 2022 |
| 36028784 | PD-L1 protein expression in relation to recurrence score values in early-stage ERâ¿¿+â¿¿breast cancer. | Breast Cancer Res Treat | 2022 |
| 35439025 | Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 35377948 | Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. | Clin Cancer Res | 2022 |
| 36344517 | Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. | NPJ Breast Cancer | 2022 |
| 35623341 | Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. | Cancer Cell | 2022 |
| 36206298 | A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. | PLoS ONE | 2022 |
| 35869114 | Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. | NPJ Breast Cancer | 2022 |
| 35550723 | Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. | Ann Oncol | 2022 |
| 35417011 | Cancer Relevance of Human Genes. | J Natl Cancer Inst | 2022 |
| 36125946 | The effectiveness of immune checkpoint inhibitors in the neoadjuvant and post-neoadjuvant breast cancer settings. | Clinical Advances in Hematology and Oncology | 2022 |